



Express Mail No.: ED 181732814 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Srivastava et al.

Confirmation No.: 8478

Serial No.: 09/625,137

Art Unit: 1643

Filed: July 25, 2000

Examiner: Christopher H. Yaen

For: ALPHA (2) MACROGLOBULIN  
RECEPTOR AS A HEAT SHOCK  
PROTEIN RECEPTOR AND USES  
THEREOF

Attorney Docket No: 8449-123-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Mail Stop RCE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references A03-A10, B01-B04, and C02-C38 listed on the attached form entitled "List of References Cited by Applicant." Copies of references A10, B01-B04, and C02-C38 are enclosed.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached List of References Cited by Applicant, and that they be made of record in the file history of the above-identified application.

Pursuant to 37 CFR § 1.97(c), Applicants believe that no fee is due for filing this Supplemental Information Disclosure Statement. However, should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 24, 2006

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

Enclosures



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-123-999

APPLICATION NO.

09/625,137

APPLICANT

Srivastava et al.

FILING DATE

July 25, 2000

ART UNIT

1643

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A03	5,112,298	5/12/1992	Prince et al.	
	A04	5,554,293	9/10/1996	Uhoch	
	A05	5,637,082	6/10/1997	Pages et al.	
	A06	5,846,928	12/8/1998	Kishida	
	A07	6,027,731	2/22/2000	Pauza	
	A08	6,033,561	3/7/2000	Schoendorfer	
	A09	6,333,311	12/25/2001	Nuijens et al.	
	A10	09/668,724	9/22/2000	Srivastava et al.	

**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	WO 94/14471	7/7/1994	Washington University		
	B02	WO 00/38760	7/6/2000	Occulogix Corp		
	B03	WO 00/54801	9/21/2000	Entremed Inc (US)		
	B04	WO 02/07755	1/3/2002	The General Hospital Corporation		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C02	Basu et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C03	Bellone et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C04	Binder and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C05	Binder et al., 2001, "Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91," J. Immunol. 166(8):4968-72	
	C06	Binder et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C07	Binder et al., 2002, "Naturally formed artificially reconstituted non-covalent alpha 2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity," Cancer Immunity 2:16-24	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1630179v1



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-123-999

APPLICATION NO.

09/625,137

APPLICANT

Srivastava et al.

FILING DATE

July 25, 2000

ART UNIT

1643

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C08	Binder et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C09	Bosch et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C10	D'Andrea, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C11	Dermer, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C12	Epplen et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C13	Fay et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C14	Freshney, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C15	Gaiger et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C16	Goto and Tanzi, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C17	Gura, 1997, "Systems for identifying new drugs are often faulty," Science 278:1041-1042	
	C18	Herz and Strickland, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784	
	C19	Houghten et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86	
	C20	Hunter, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63	
	C21	James, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47	
	C22	Kornfeld et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133	
	C23	Kuhlmann et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552	
	C24	McKee and Collins, 1974, "Intravascular Leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia," Medicine 53: 463-478	
	C25	The Merck Manual of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872	
	C26	Millward and Hoeltge, 1982, "The Historical Development of Automated Hemapheresis", J. of Clin. Apheresis 1: 25-32	
	C27	Pineda et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4	
	C28	Proud, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82	
	C29	Report of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984	
	C30	Singh, 1997, "Neuroautoimmunity: pathogenic implications for Alzheimer's disease," Gerontology 43:79-94	
	C31	Sotgiu et al., 1998, "Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study," Acta. Neurol. Scand. 98(5):314-7	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1630179v1



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO. <b>8449-123-999</b>	APPLICATION NO. <b>09/625,137</b>
APPLICANT <b>Srivastava et al.</b>	
FILING DATE <b>July 25, 2000</b>	ART UNIT <b>1643</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C32	Spero et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22	
	C33	Srivastava, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol. 2(3): 185-194	
	C34	Tait, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11	
	C35	Urbaniak and Robinson, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review	
	C36	Weiner et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33	
	C37	Weiner et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884	
	C38	Wong et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	